The Wall Street Journal: Merck in talks to buy cancer biotech Seagen for about $40 billion


Merck & Co.


is in advanced talks to acquire Seagen Inc.

and is aiming to finalize a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.

The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck’s second fiscal-quarter earnings, set for July 28, the people said. Seagen’s stock closed at $175.13 on Wednesday.

The Wall Street Journal: Samsung Electronics expects smaller-than-expected Q2 profit as demand sags

Previous article

Dow Jones Newswires: India’s central bank takes steps to stem rupee’s slide

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News